COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,788 Articles (22,523 medRxiv, 8,265 bioRxiv)

Most recent first Previous |  Page 787: Articles 7861-7870  | Next

Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals
Leiner, J., Pellissier, V., Hohenstein, S., Koenig, S., Schuler, E., Moeller, R., Nachtigall, I., Bonsignore, M., Hindricks, G., Kuhlen, R., BOLLMANN, A.
10.1101/2022.04.09.22273420 — Posted: 2022-04-10
NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses
Rydyznski Moderbacher, C., Kim, C., Mateus, J., Plested, J., Zhu, M., Cloney-Clark, S., Weiskopf, D., Sette, A., Fries, L., Glenn, G., Crotty, S.
10.1101/2022.04.08.487674 — Posted: 2022-04-08
SARS-CoV-2 and its variants, but not Omicron, induces thymic atrophy and impaired T cell development
Rizvi, Z. A., Sadhu, S., Dandotiya, J., Binayke, A., Sharma, P., Singh, V., Das, V., Khatri, R., Kumar, R., Samal, S., Kalia, M., Awasthi, A.
10.1101/2022.04.07.487556 — Posted: 2022-04-08
SARS-CoV-2 mutations affect proteasome processing to alter CD8+ T cell responses
Wellington, D., Yin, Z., Yu, Z., Heilig, R., Davis, S., Fischer, R., Felce, S. L., Hublitz, P., Beveridge, R., Dong, D., Liu, G., Yao, X., Peng, Y., Kessler, B. M. M., Dong, T.
10.1101/2022.04.08.487623 — Posted: 2022-04-08
Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike
Stalls, V., Lindenberger, J., Gobeil, S., Henderson, R., Parks, R., Barr, M., Deyton, M., Martin, M., Janowska, K., Huang, X., May, A., Speakman, M., Beaudoin, E., Edwards, R. J., Eaton, A., Montefiori, D., Williams, W., Saunders, K. O., Wiehe, K., Haynes, B. F., Acharya, P.
10.1101/2022.04.07.487528 — Posted: 2022-04-08
Hippo Signaling Pathway Activation during SARS-CoV-2 Infection Contributes to Host Antiviral Response
Garcia, G., Wang, Y., Irudayam, J. I., Jeyachandran, A. V., Cario, S. C., Sen, C., Li, S., Li, Y., Kumar, A., Nielsen-Saines, K., French, S. W., Shah, P. S., Morizono, K., Gomperts, B., Deb, A., Ramaiah, A., Arumugaswami, V.
10.1101/2022.04.07.487520 — Posted: 2022-04-08
The Delta variant SARS-CoV-2 spike protein uniquely promotes aggregation of pseudotyped viral particles
Petersen, J. D., Lu, J., Fitzgerald, W., Zhou, F., Blank, P. S., Matthies, D., Zimmerberg, J.
10.1101/2022.04.07.487415 — Posted: 2022-04-08
Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants
Mammedov, T., Yuksel, D., Grbzaslan, I., Ilgn, M., Gulec, B., Mammadova, G., Ozdarendeli, A., Islam Pavel, S. T., Yetiskin, H., Kaplan, B., Uygut, M. A., Hasanova, G.
10.1101/2022.04.07.487347 — Posted: 2022-04-08
Built environment's impact on COVID-19 transmission and mental health revealed by COVID-19 Participant Experience data from the All of Us Research Program
Luo, W., Baldwin, E., Jiang, A. Y., Li, S., Yang, B., Li, H.
10.1101/2022.04.05.22273358 — Posted: 2022-04-07
Risk factors for severe COVID-19 in hospitalized children in Canada: A national prospective study from March 2020--May 2021
Farrar, D. S., Drouin, O., Moore Hepburn, C., Baerg, K., Chan, K., Cyr, C., Donner, E. J., Embree, J. E., Farrell, C., Forgie, S., Giroux, R., Kang, K. T., King, M., Laffin Thibodeau, M., Orkin, J., Ouldali, N., Papenburg, J., Pound, C. M., Price, V. E., Proulx-Gauthier, J.-P., Purewal, R., Ricci, C., Sadarangani, M., Salvadori, M. I., Thibeault, R., Top, K. A., Viel Theriault, I., Kakkar, F., Morris, S. K.
10.1101/2022.04.06.22273409 — Posted: 2022-04-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).